An interview with MSH CEO Jonathan Quick: Tackling chronic disease in low-income countries
Last September, Novartis Access became the first industry program focused on the affordability and availability of medicines addressing key noncommunicable diseases (NCDs): cardiovascular diseases, diabetes, respiratory illnesses and breast cancer. Such chronic illnesses are a major and growing challenge in the developing world. Already today, 28 million people die each year from chronic diseases in lower-income countries – representing nearly 75% of deaths from NCDs globally.
Novartis Access already launched in Kenya and Ethiopia, with first deliveries hitting the ground this week in Kenya.
Expanding access to healthcare and medicines often faces multiple challenges, such as shortages of trained healthcare professionals, poor understanding of chronic diseases, lack of healthcare infrastructure in rural areas and unreliable distribution networks for medical supplies. Novartis is collaborating with governments and nonprofit organizations to help overcome these challenges. One key partner in Kenya is Management Sciences for Health (MSH). MSH is a global health nonprofit that strengthens health systems and is working to help ensure supply chain integrity of Novartis Access – so that the medicines reach the people who need them.
Dr. Jonathan D. Quick, President and CEO of MSH, shares his views on how we can best address NCDs in the developing world.